Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) belonging to the growth hormone releasing peptide (GHRP) class. It was developed in the 1990s with the explicit goal of creating a growth hormone secretagogue that selectively triggers GH release without activating the off-target pathways that make older GHRPs problematic for long-term use.
It binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs with high affinity, triggering a pulse of growth hormone release. What distinguishes it from earlier GHRPs is its selectivity — it does not meaningfully activate the ACTH/cortisol pathway or the prolactin pathway, making it substantially cleaner for repeated use.
The Selectivity Advantage
The defining characteristic of ipamorelin relative to the GHRP family is its receptor selectivity profile:
- GH release: Strong and consistent pulsatile GH stimulation — the intended effect
- Cortisol: Negligible increase at standard doses. This is critical — cortisol elevation from older GHRPs like GHRP-6 and hexarelin counteracts the anabolic and recovery benefits of GH by promoting catabolism and insulin resistance.
- Prolactin: No significant elevation. Prolactin increase from some GHRPs can suppress testosterone and libido.
- Hunger stimulation: Minimal at standard doses. GHRP-6 causes pronounced hunger via ghrelin elevation — ipamorelin's pharmacological refinement largely eliminates this.
- ACTH: No significant activation of adrenal axis. The GHRP-6 → cortisol connection is effectively removed in ipamorelin's design.
This selectivity profile is why ipamorelin has largely replaced GHRP-6 and GHRP-2 as the preferred GHRP in longevity medicine protocols.
The CJC-1295 Combination Rationale
Ipamorelin (GHRP, ghrelin receptor pathway) and CJC-1295 (GHRH analogue, GHRH receptor pathway) work through completely independent receptor systems on pituitary somatotrophs. When combined, they activate two separate intracellular signaling cascades simultaneously — IP3/DAG for the ghrelin receptor and cAMP for the GHRH receptor — resulting in a synergistic GH pulse that can be substantially larger than either compound alone.
Published research suggests the combination produces GH pulses 3-10 times greater than either compound administered alone, depending on dose and individual pituitary reserve. This synergy is the foundation of the most commonly used GH optimization protocol in longevity medicine.
Protocol: CJC-1295 no-DAC (100-200mcg) + ipamorelin (100-300mcg) combined in a single syringe, injected subcutaneously 30-60 minutes before sleep. CJC-1295 no-DAC is preferred over the DAC version for maintaining pulsatile rather than sustained GH release.
The Sleep Timing Protocol and Why It Matters
The largest natural GH pulse in healthy adults occurs 30-60 minutes after sleep onset, coinciding with the first episode of slow-wave (deep) sleep. This nocturnal pulse accounts for the majority of total daily GH secretion in adults, particularly those over 40 where daytime GH pulses have substantially declined.
Injecting ipamorelin (or the CJC-1295/ipamorelin combination) 30-60 minutes before sleep achieves two goals simultaneously:
- The peptide's peak action aligns with the pituitary's natural priming state for the nocturnal GH pulse, amplifying rather than interrupting it
- Sleep itself potentiates the GH response — deep sleep promotes further GH release via somatostatin suppression
Carbohydrate or caloric intake within 2 hours of injection substantially blunts the GH response through insulin-mediated somatostatin release. This is a practically significant interaction — Indian eating patterns that include late dinners close to sleep time can significantly reduce peptide efficacy.
Who May Benefit
The strongest rationale for ipamorelin use exists in specific populations:
- Adults over 40 with low-normal IGF-1: GH pulsatility naturally declines with age — by age 40-50, GH secretion is often 30-50% of peak. Ipamorelin can partially restore this decline.
- Athletes and fitness-focused individuals: Improved sleep quality, enhanced muscle protein synthesis, and better recovery from training.
- Those with sleep quality issues: The GH pulse improvement during deep sleep often reports as better sleep quality subjectively.
- Body composition focus: In combination with appropriate training and nutrition, for lean mass gains and fat reduction over 3-6 month cycles.
GHRP Comparison Table
| Property | Ipamorelin | GHRP-6 | GHRP-2 | Hexarelin |
|---|---|---|---|---|
| GH pulse potency | Moderate-strong | Strong | Strong | Very strong |
| Hunger stimulation | Minimal | Significant | Moderate | Moderate |
| Cortisol elevation | Negligible | Significant | Moderate | Significant |
| Prolactin elevation | Negligible | Moderate | Moderate | Moderate |
| Selectivity | High — GH selective | Low — broad GHRP effects | Moderate | Low — also cardiac CD36 |
| Tachyphylaxis risk | Low with cycling | Moderate | Moderate | High |
| Best use case | Daily long-term longevity use | Appetite stimulation, max GH burst | Strong GH cycle with managed side effects | Short cycles, cardiac interest |
Monitoring Protocol
- IGF-1: Baseline before starting; retest at 8-12 weeks; target upper third of age-adjusted range
- Fasting glucose: Baseline and at 3 months — GH can affect insulin sensitivity
- Sleep quality: Subjective tracking weekly; often the earliest improvement signal
- Body composition: DEXA or consistent waist measurement at 3-month intervals
- Cortisol (AM): Consider baseline check — ipamorelin shouldn't elevate, but confirms selectivity in your case
Cycle Protocol
Standard cycling recommendations used in clinical practice:
- On cycle: 8-12 weeks of nightly injection
- Off period: 4-8 weeks without peptides (allows receptor sensitivity restoration)
- Rationale for cycling: While ipamorelin has lower tachyphylaxis risk than older GHRPs, pituitary receptor desensitization can occur with continuous long-term use. Cycling prevents this.
- IGF-1 check timing: At weeks 8-10 of the on cycle to capture peak response
Frequently Asked Questions
Ipamorelin is generally preferred for longevity and long-term use due to its selectivity. GHRP-6 causes significant hunger (via ghrelin elevation), meaningful cortisol and prolactin elevation, and has higher tachyphylaxis potential. Ipamorelin was specifically engineered to remove these off-target effects while preserving the GH pulse. For most adults using GH optimization as a longevity tool, ipamorelin is the cleaner choice.
Inject subcutaneously 30-60 minutes before sleep on an empty stomach (no food 2+ hours prior). Combine with CJC-1295 no-DAC for synergistic effect. Use insulin syringes for minimal discomfort. Maintain consistent sleep timing. Cycles of 8-12 weeks on, 4-8 weeks off. Track IGF-1 at weeks 8-10 to confirm response. Avoid carbohydrates near injection time.
Via GH and IGF-1 elevation, ipamorelin promotes lean mass accretion and fat oxidation, particularly visceral fat reduction. Effects become apparent over 3-6 months. Training and adequate protein intake (1.6-2g/kg) are necessary to see meaningful lean mass changes. Sleep quality improvement is typically the first reported benefit.
100-300mcg subcutaneously per injection is the range used in research and clinical practice. Most protocols use 200-300mcg before sleep. Inject on an empty stomach (2+ hour fast from food). Combine with CJC-1295 no-DAC 100-200mcg in the same syringe for amplified effect. Consistent pre-sleep timing is more important than dose precision.